Thiti Susiriwatananont

Dr. Thiti Susiriwatananont

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2025 in Cells
Verified
Journal Article
Open access
PDF file
TSThiti Susiriwatananont
Thiti Susiriwatananont
PEPanuch Eiamprapaporn
Panuch Eiamprapaporn
MRMaria Vazquez Roque
Maria Vazquez Roque
FFFrancis A. Farraye
Francis A. Farraye
APAdam Perlman
Adam Perlman
SCSaranya Chumsri
Saranya Chumsri
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their benefits remain limited to a subset of patients, underscoring the need for more reliable biomarkers and novel therapeutic strategies. The gut microbiome has emerged as a critical modulator of systemic immunity and a promising determinant of ICI response. Evidence links specific microbial features, taxa, and bioactive metabolites to enhanced antitumor immunity, whereas disruptions, such as antibiotic exposure, are associated with poorer outcomes. Advances in sequencing and multi-omics technologies have provided more profound insights into microbiome-immune crosstalk, though methodological heterogeneity continues to challenge reproducibility. Translational studies demonstrate that microbiome-based intervention, including fecal microbiota transplantation (FMT), biotics supplementation, and engineered microbial strains, can enhance ICI efficacy or mitigate immune-related toxicities. Despite encouraging early clinical signals, broader implementation requires methodological rigor, standardized protocols, and innovative trial designs that account for host and environmental factors. For clinicians, the most immediate strategies involve prudent antibiotic stewardship and patient enrollment in microbiome-focused clinical trials. Overall, the gut microbiome is a promising biomarker and a therapeutic target, representing a new frontier for personalizing immunotherapy and improving patient outcomes in oncology.

24 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TSThiti Susiriwatananont
Thiti Susiriwatananont
PEPanuch Eiamprapaporn
Panuch Eiamprapaporn
MRMaria Vazquez Roque
Maria Vazquez Roque
FFFrancis A. Farraye
Francis A. Farraye
APAdam Perlman
Adam Perlman
SCSaranya Chumsri
Saranya Chumsri
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their benefits remain limited to a subset of patients, underscoring the need for more reliable biomarkers and novel therapeutic strategies. The gut microbiome has emerged as a critical modulator of systemic immunity and a promising determinant of ICI response. Evidence links specific microbial features, taxa, and bioactive metabolites to enhanced antitumor immunity, while disruptions such as antibiotic exposure are associated with poorer outcomes. Advanced in sequencing and multi-omics technologies have provided deeper insights into microbiome-immune crosstalk, though methodological heterogeneity continues to challenge reproducibility. Translational studies demonstrate that microbiome-based intervention, including fecal microbiota transplantation (FMT), biotics supplementation, and engineered microbial strains, can enhance ICI efficacy or mitigate immune-related toxicities. Despite encouraging early clinical signals, broader implementation requires methodological rigor, standardized protocols, and innovative trial designs that account for host and environmental factors. For clinicians, the most immediate strategies involve prudent antibiotic stewardship and patient enrollment in microbiome-focused clinical trials. Overall, the gut microbiome represents both a predictive biomarker and a therapeutic target, offering a new frontier to refine immunotherapy and improve patient outcomes in oncology.

1 January 2025 in International Journal of Breast Cancer
Verified
Journal Article
Open access
TSThiti Susiriwatananont
Thiti Susiriwatananont
CWConcord Wongkraisri
Concord Wongkraisri
TDThanate Dajsakdipon
Thanate Dajsakdipon
ASArchara Supavavej
Archara Supavavej
ADArunee Dechaphunkul
Arunee Dechaphunkul
NPNapa Parinyanitikul
Napa Parinyanitikul
Purpose: HER2‐low status is a predictive factor for novel anti‐HER2 therapies in metastatic hormone receptor–positive breast cancer (HR+ MBC). However, its impact on endocrine therapy outcomes remains uncertain. We aimed to explore the effect of HER2‐low and HER2‐zero status in HR+ MBC patients treated with first‐line aromatase inhibitors (AIs) with or without CDK4/6 inhibitors (CDK4/6i). Methods: We retrospectively reviewed postmenopausal women with HR+ MBC treated with first‐line AI ± CDK4/6i between January 1, 2017, and December 31, 2022, from six tertiary hospitals in Thailand. HER2‐low was defined as HER2 IHC 1+ or IHC 2+ with ISH‐negative. Progression‐free survival (PFS) and overall survival (OS) were compared in unadjusted and adjusted cohorts using stabilized inverse probability of treatment weighting (sIPTW), adjusting for age, ECOG performance status, de novo metastasis, endocrine sensitivity, visceral metastasis, number of metastatic sites, and treatment year. Interaction analyses were performed to assess effect modification by HER2 status and other clinical subgroups. Results: Among 504 patients, 219 (43.5%) were HER2‐low, and 285 (56.5%) were HER2‐zero. Median follow‐up was 31 months (IQR 19–47). CDK4/6i + AI was administered to 52.5% of HER2‐low and 43.9% of HER2‐zero patients. After sIPTW adjustment, CDK4/6i + AI prolonged median PFS to 22.1 months compared with 21.5 months for AI alone in the HER2‐low cohort (HR = 0.80, 95% CI 0.54–1.18; p = 0.26) and to 20.1 months compared with 13.5 months in the HER2‐zero cohort (HR = 0.65, 95% CI 0.45–0.93; p = 0.02). Median OS was 49.3 months with CDK4/6i + AI versus 48.4 months with AI alone in HER2‐low (HR = 0.81, 95% CI 0.48–1.36; p = 0.43) and 45.8 versus 42.3 months in HER2‐zero (HR = 0.85, 95% CI 0.43–1.05; p = 0.52). Subgroup analyses showed consistent benefit of CDK4/6i + AI across most clinical categories. The interaction test for treatment × HER2 status was not significant (HR = 1.21, 95% CI 0.74–1.98; p = 0.44), indicating no effect modification by HER2‐low status. Conclusions: HER2‐low status was not associated with prognosis or predictive value for CDK4/6i efficacy, supporting CDK4/6i + AI as the standard first‐line therapy irrespective of HER2 expression level.

1 June 2026 in JMIR Formative Research
Verified
Journal Article
Open access
NSNarawitch Sompornpailin
Narawitch Sompornpailin
TSThiti Susiriwatananont
Thiti Susiriwatananont
VSVirote Sriuranpong
Virote Sriuranpong
STSuebpong Tanasanvimon
Suebpong Tanasanvimon
CVChanida Vinayanuwattikun
Chanida Vinayanuwattikun
NPNapa Parinyanitikul
Napa Parinyanitikul
Background: Chemotherapy-related toxicities often lead to unscheduled health care use and diminished quality of life. Digital health interventions, such as chatbots, offer a scalable solution for supportive care; however, evidence regarding their effectiveness in resource-limited, low- and middle-income settings remains limited. Objective: This study aimed to evaluate the feasibility, use, and preliminary effectiveness of a closed-loop chatbot (ChulaCancer Chatbot) in reducing unscheduled hospital visits and stabilizing quality of life among patients receiving chemotherapy for breast or colorectal cancer. Methods: This pilot randomized controlled trial enrolled 40 patients at a single academic center in Thailand, randomized 1:1 to either ChulaCancer chatbot plus usual care or usual care alone. The primary end point was the proportion of unscheduled hospital visits due to chemotherapy-related toxicities within 12 weeks of treatment initiation. Secondary end points included longitudinal quality of life changes (30-item EORTC Quality of Life Questionnaire) measured at baseline, following chemotherapy cycle 2, and following cycle 4. Use metrics were extracted from the chatbot platform. Data were analyzed using the Fisher exact test and linear mixed-effects models. Results: The platform recorded 2393 total messages with a 70.5% (503/713) successful response rate for user-initiated queries. Unscheduled hospital visits occurred in 15% (3/20) of the chatbot group compared to 35% (7/20) of the usual care group (P=.24). While infection-related visits were similar between groups, the usual care group recorded multiple visits for low-acuity symptoms (eg, anxiety, headache, and edema) that were absent in the chatbot group. Regarding quality of life, the chatbot group demonstrated a significant mitigation of cancer-related fatigue following cycle 4 compared with the usual care group (P=.02 between groups). Additionally, the chatbot group significantly improved in global health status (P=.04) and avoided the decline in physical functioning observed in the control arm (P=.04). Conclusions: The integration of a closed-loop chatbot into oncology care is feasible and provides a potential secure triage mechanism that may reduce acute care use for low-acuity concerns. Future large-scale trials incorporating agentic artificial intelligence are warranted to further validate clinical and economic benefits. Trial Registration: Thai Clinical Trials Registry TCTR20251220014; https://tinyurl.com/5b6k3e63

9 June 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Purpose: To evaluate the safety and immunogenicity of intramuscularly delivered personalized neoantigen synthetic long peptide (SLP) vaccines in patients with advanced solid tumors. Patients and Methods: In this phase I trial, 12 patients with advanced melanoma (n = 9) or renal cell carcinoma (n = 3) who lacked access to further reimbursed standard therapies at enrollment received intramuscular neoantigen SLP vaccines with Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC). Each vaccine contained about 20 predicted neoantigen peptides. Adverse events were monitored throughout vaccination and follow-up. Immune profiling was performed at baseline and predefined postvaccination time points. Results: Intramuscular neoantigen vaccination was well tolerated, with only grade 1 to 2 local pain or fever and no immune-mediated toxicities. All participants developed de novo T-cell responses, which were detectable as early as 1 week after vaccination in most patients. On average, 53% of peptides per patient were immunogenic, inducing both CD8+ and CD4+ neoantigen-specific responses. Patients previously treated with immune checkpoint inhibitors (ICI) had higher baseline immunity but achieved comparable postvaccination responses to ICI-naïve patients. IFNγ-dominant CD8+ and TNFα-dominant CD4+ responses were observed, along with increased effector memory differentiation. Two patients with higher CD8+ terminal effector memory RA (TEMRA) proportions were the longest survivors. Tumor biopsies revealed enhanced CD8+ infiltration, and epitope spreading occurred in two evaluable cases. An analysis of 239 peptides showed greater immunogenicity for dual MHC I/II–binding, cysteine-containing, in-frame insertions or deletions–derived or low variant allele frequency–derived mutations, whereas proline substitutions reduced responses. Conclusions: Intramuscular neoantigen SLP vaccination with poly-ICLC is safe and induces rapid, mutation-specific T-cell immunity with robust CD8+ effector responses. These findings support intramuscular administration as a promising strategy for peptide-based cancer vaccines.

14 September 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
STSarina Tangyingyong
Sarina Tangyingyong
HAHala Abu-Fares
Hala Abu-Fares
TSThiti Susiriwatananont
Thiti Susiriwatananont
Early-onset colorectal cancer (eoCRC) is increasing globally, raising interest in modifiable dietary exposures that may contribute to its development. High fructose intake, particularly from sugar-sweetened beverages and high-fructose corn syrup, has been associated with colorectal neoplasia and eoCRC in epidemiologic studies. Experimental evidence suggests that fructose may promote colorectal tumorigenesis through enhanced uptake and metabolism, polyol pathway activation, glycolytic and lipogenic reprogramming, hypoxic adaptation, and interactions with the tumor microenvironment. Excess fructose reaching the colon may also impair intestinal barrier integrity and alter gut microbial composition and metabolite production. Preclinical models support a direct tumor-promoting effect of fructose independent of obesity, whereas human mechanistic and microbiome data remain limited. This review summarizes current evidence linking fructose exposure with eoCRC and discusses emerging metabolic, microbial, and translational implications, while highlighting key gaps that must be addressed to establish causality and clinical relevance.